Inhibition of JNK/c-Jun-ATF2 Overcomes Cisplatin Resistance in Liver Cancer through down-Regulating Galectin-1

Due to drug resistance, the clinical response to cisplatin (CDDP) from patients with liver cancer is unsatisfactory. The alleviation or overcoming of CDDP resistance is an urgent problem to be solved in clinics. Tumor cells rapidly change signal pathways to mediate drug resistance under drug exposur...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of biological sciences 2023-01, Vol.19 (8), p.2366-2381
Hauptverfasser:	Yang, Fan, Li, Mengzhu, Xu, Duo, Jiang, Zebo, Jiang, Hailong, Xiao, Yitai, Mei, Chaoming, Yang, Meilin, Chen, Congmin, Zhou, Bin, He, Bailiang, Shan, Hong, Pang, Pengfei, Li, Dan
Format:	Artikel
Sprache:	eng
Schlagworte:	Activating Transcription Factor 2 - genetics Activating Transcription Factor 2 - metabolism Antibodies Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Apoptosis Bioluminescence c-Jun protein Cancer therapies Cell Line, Tumor Cells Chemotherapy Cisplatin Cisplatin - pharmacology Cisplatin - therapeutic use Colorectal cancer DNA damage Drug resistance Drug Resistance, Neoplasm - genetics Galectin 1 - genetics Galectin-1 Hepatocytes Humans JNK Mitogen-Activated Protein Kinases - metabolism JNK protein Kinases Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - genetics Medical prognosis Membranes Phosphors Plasmids Proteins Research Paper Transcription factors Tumor cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!